- Citations, last 5 years
- 1 743
- Works, last 5 years
- 120
- h-index
- 104
- Scientists listed
- 30
- Grants since 2016
- 9
Grants received
2024–2026 · research · R43
Development of a Machine Learning Algorithm to Detect Opioid Withdrawal and Cravings to Increase Treatment Retention
Navid Khodaparast · Spark Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Delivering Transcutaneous Auricular Neurostimulation to Improve Treatment Retention in Opioid Use Disorder
Navid Khodaparast · Spark Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Delivering Transcutaneous Auricular Neurostimulation to Improve Treatment Retention in Opioid Use Disorder
Navid Khodaparast · Spark Therapeutics (United States) · funded by National Institutes of Health
2019–2023 · research · R44
Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome
Dorothea Denise Jenkins · Spark Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Delivering Transcutaneous Auricular Neurostimulation as an Adjunct Treatment for Neonatal Opioid Withdrawal Syndrome
Dorothea Denise Jenkins · Spark Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Developing a prenatal biologic therapy to mitigate ASD risk from maternal autoantibodies to Caspr2
Ronald M Burch · Spark Therapeutics (United States) · funded by National Institutes of Health
2017–2018 · research · R43
A diagnostic for maternal autoAb to Caspr2 to predict increased risk of autism spectrum disorder in children
Ronald M Burch · Spark Therapeutics (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Developing a prenatal biologic therapy to mitigate ASD risk from maternal autoantibodies to Caspr2
Ronald M Burch · Spark Therapeutics (United States) · funded by National Institutes of Health
2016–2018 · grant · Standard Grant
SBIR Phase II: Large-scale Creative Thinking Assessment for the Workforce
Farzad Eskafi · Spark Therapeutics (United States) · funded by National Science Foundation